Issue of shares, PDMR Dealing and TVR
("RenalytixAI", the "Company" or the "Group")
Issue of shares under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights
The purchase of ADSs by certain employees of the Company who are treated as affiliates under
An application will be made to the
Total voting rights
Following Admission, the Company will have 72,047,286 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 72,047,286.
For further information, please contact:
|
||||
|
Via Walbrook PR |
|||
|
|
|||
Stifel (Nominated Adviser & Joint Broker) |
Tel: 020 7710 7600 |
|||
|
|
|||
|
|
|||
|
Tel: 020 7597 4000 |
|||
|
|
|||
|
|
|||
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com
|
|||
|
Mob: 07980 541 893 / 07584 391 303 |
|||
About Kidney Disease
Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The
* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI
RenalytixAI is a developer of clinical grade, artificial intelligence-enabled in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, and patient stratification for drug clinical trials. For more information, visit renalytixai.com
Notification of dealings in shares by PDMRs of the Company:
1. |
Details of PDMR / PDMR Associate |
|
(a) |
|
|
(b) |
Position / status |
Chief Financial Officer |
(c) |
Initial notification / amendment |
Initial Notification |
2. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
(d) |
Description of the financial instrument |
Acquisition of Ordinary Shares to be converted to American Depositary Shares |
(e) |
Nature of the transaction |
Acquisition of shares |
(f) |
Price(s) and volume(s) |
Price: Volume: 4,596 shares
|
(g) |
Aggregated information Aggregated volume Price |
4,596 shares |
(h) |
Date of the transaction |
|
(i) |
Place of the transaction |
Outside a trading venue |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the